Video

Dr. Singal on Downstaging Strategies in HCC

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

Amit Singal, MD, medical director of the Liver Tumor Program and clinical chief of hepatology at the University of Texas Southwestern Medical Center, discusses downstaging strategies for patients with hepatocellular carcinoma (HCC).

When patients present within the traditional Milan Criteria for Liver Transplant in the United States, disease management is straightforward, according to Singal. Patients who fall within these criteria have excellent long-term survival, Singal says. Along with recognizing the patients who were achieving long-term survival, the HCC community has also begun to acknowledge that those with larger intrahepatic tumor burden could be downstaged, Singal notes.

This can be achieved through locoregional therapies, which can help patients to fall within criteria after achieving a response to treatment. Some of these approaches include chemotherapy embolization, radiotherapy embolization, or stereotactic body radiation therapy, Singal notes. Patients who have been downstaged after responding to treatment are able to achieve excellent long-term survival that is on par with those who started and stayed within criteria, Singal concludes.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center